Shots:

• Skyhawk will deploy its SkySTARTM platform to develop drug candidates targeting autoimmune and metabolic diseases and will receive an up front $600M/target while Merck get an option to exclusively license WW IP rights to candidates- discovered and developed under the agreement
• If Merck exercises its option- Skyhawk will receive an option fees- milestones and royalties on sales of approved products resulting from the collaboration while Merck will be responsible for development & commercialization. The collaboration now covers neurodegeneration- oncology- autoimmunity- and metabolic diseases
• The expanded collaboration in autoimmune and metabolic diseases reflects SkySTARTM platform's ability to advance small molecules- addressing the unmet medical needs of patients

Click here ­to­ read full press release/ article 

Ref: PRNewswire | Image: Merck